Get started
Author

Editta Baldini

Observed names: Baldini Editta, E. Baldini, Edi Editta Baldini
Observed institution: Gruppo Oncologico del Nord Ovest
ORCID: 0009-0006-6241-346X
Observed ORCID: 0009-0006-6241-346X
OpenAlex ID: A5050912152
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
2024 · Nicoletta Colombo, Elena Biagioli, et al. · The Lancet Oncology · 156
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
2023 · Sara Lonardi, Cosimo Rasola, et al. · Journal of Clinical Oncology · 45
PDF
“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome
2016 · Patrizia Vici, Laura Pizzuti, et al. · Oncotarget · 40
PDF
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
2025 · Kenichi Harano, Roldano Fossati, et al. · Journal of Gynecologic Oncology · 39
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
2025 · P. Ciracì, M.M. Germani, et al. · Annals of Oncology · 26
PDF
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort
2024 · Rossella Bruno, Anello Marcello Poma, et al. · Cancers · 15
PDF
Dissecting Signaling Pathways in Hepatocellular Carcinoma: New Perspectives in Medical Therapy
2014 · Lorenzo Fornaro, Caterina Vivaldi, et al. · Future Oncology · 13
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
2019 · Laura Pizzuti, Eriseld Krasniqi, et al. · International Journal of Cancer · 10
PDF
35MO Quality-adjusted survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
2024 · M.P. Barretina Ginesta, S. Uggeri, et al. · ESMO Open · 1
PDF
A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of HRD-positive ovarian tumours (IOlanTHe).
2024 · Federica Tomao, Lara Paracchini, et al. · Journal of Clinical Oncology
PDF
Fulvestrant After Failur of Adjuvant Hormonal Therapy: Multicenter Retrospective Observational Study
2012 · O. Garrone, C. Bighin, et al. · Annals of Oncology
Integrative approaches of diet and complementary medicine for the treatment of chemotherapy and hormone therapy side effects in patients with solid tumour: experience in the hospital of Lucca (Italy)
2012 · Pellegrini Manuela, Rossi Elio, et al. · European Journal of Integrative Medicine
Works count: 12
Citation count: 345
H-index: 8
I10-index: 8
Year
Topic
Type